ProQR Therapeutics (PRQR) Net Income towards Common Stockholders (2012 - 2026)

ProQR Therapeutics has reported Net Income towards Common Stockholders for 15 years, with the latest figure at -$15.7 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 47.79% year-over-year to -$15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.3 million (down 60.01% YoY) and the FY2025 annual result came in at -$49.1 million, down 65.51% from the prior year.
• Net Income towards Common Stockholders retreated to -$15.7 million in Q1 2026 per PRQR's latest filing, from -$9.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$2.9 million in Q2 2024 and troughed at -$23.5 million in Q3 2022.
• A 5-year average of -$11.2 million and a median of -$9.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders jumped 72.01% in 2023, then sank 402.18% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$13.6 million in 2022, then surged by 60.85% to -$5.3 million in 2023, then plunged by 85.19% to -$9.8 million in 2024, then gained by 7.16% to -$9.1 million in 2025, then tumbled by 71.6% to -$15.7 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$15.7 million, -$9.1 million, and -$12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.